Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission.

EJNMMI radiopharmacy and chemistry·2018
Same author

Pretargeted PET Imaging Using a Bioorthogonal <sup>18</sup>F-Labeled trans-Cyclooctene in an Ovarian Carcinoma Model.

Bioconjugate chemistry·2017
Same author

Al<sup>18</sup>F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging.

Theranostics·2017
Same author

Synthesis and preclinical evaluation of [<sup>11</sup>C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL).

European journal of medicinal chemistry·2017
Same author

Micro-flow photosynthesis of new dienophiles for inverse-electron-demand Diels-Alder reactions. Potential applications for pretargeted <i>in vivo</i> PET imaging.

Chemical science·2017
Same author

Preclinical Evaluation of <sup>18</sup>F-JNJ64349311, a Novel PET Tracer for Tau Imaging.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2017

Related Experiment Video

Updated: May 28, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Marlein Miranda Cona1, Huaijun Wang, Junjie Li

  • 1Radiology Section, Department of Medical Diagnostic Sciences, Biomedical Sciences Group, University of Leuven, Leuven, Belgium.

Investigational New Drugs
|October 19, 2011
PubMed
Summary

New targeted radiotherapies using agents that bind to tumor necrosis offer improved cancer treatment. These agents accumulate in necrotic areas, targeting residual cancer cells effectively for better outcomes.

More Related Videos

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: May 28, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

  • Oncology
  • Radiotherapy
  • Molecular Imaging

Background:

  • Cancer remains a leading cause of death globally, with conventional treatments often lacking curative potential.
  • Systemic targeted radiotherapy (STR) utilizes radioactive agents for precise cancer cell destruction.
  • Current STR agents like monoclonal antibodies (MoAbs) and peptides face challenges including poor tumor penetration and off-target effects.

Purpose of the Study:

  • To explore novel targeted radiotherapeutic agents for enhanced cancer treatment.
  • To evaluate agents targeting tumor necrosis for improved delivery and efficacy.
  • To investigate the potential of necrosis-targeting agents in combination with necrosis-inducing treatments.

Main Methods:

  • Review of existing literature on systemic targeted radiotherapy agents.
  • Analysis of the properties and targeting mechanisms of necrosis-avid agents.
  • Evaluation of the combined approach of necrosis-inducing treatments and subsequent targeted radiotherapy.

Main Results:

  • Monoclonal antibodies and peptides show limitations in tumor distribution, retention, and specificity.
  • Necrosis-targeting agents demonstrate high, specific, and prolonged accumulation in tumor necrotic sites.
  • The combination of necrosis-inducing treatments and necrosis-targeting agents offers a promising strategy.

Conclusions:

  • Necrosis-targeting agents represent a significant advancement in developing effective systemic targeted radiotherapy.
  • The crossfire effect from these agents can irradiate adjacent viable tumor cells, enhancing therapeutic response.
  • This approach holds promise for improving cancer treatability and curability.